Bioxcel Therapeutics Hits Record On Bullish Test Results In Schizophrenia [Investor's Business Daily]
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: Investors Business Daily
Bioxcel Therapeutics ( BTAI ) unveiled bullish results for an agitation treatment Monday — prodding BTAI stock to a record high. The biotech company 's drug reduced agitation in patients with schizophrenia and bipolar disorder in two pivotal studies. Now, Bioxcel is planning to ask for Food and Drug Administration approval in the first quarter of 2021. "These compelling Phase 3 results show that (the drug called) BXCL501, if approved, has the potential to become an important new treatment option for patients suffering from acute agitation," Bioxcel Chief Executive Vimal Mehta said in a written statement. In morning trading on the stock market today , BTAI stock rocketed 29.3% near 68.50. That gap up put the biotech stock at its highest-ever point. Shares of BTAI went public at 11 in March 2018. Researchers studied the impact of the drug at two hours. Patients showed significant reductions in agitation at both 120-microgram and 180-microgram doses. The benefit was observable as early a
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaGlobeNewswire
- BioXcel launches $25M direct offering of stock and warrants [Seeking Alpha]Seeking Alpha
- Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack [Seeking Alpha]Seeking Alpha
- BioXcel Therapeutics Announces $25 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
BTAI
Earnings
- 3/12/24 - Beat
BTAI
Sec Filings
- 4/19/24 - Form PRE
- 4/10/24 - Form 8-K
- 4/8/24 - Form 4
- BTAI's page on the SEC website